Related Experiment Videos
Deterioration in renal function associated with fibrate therapy.
J Lipscombe1, G F Lewis, D Cattran
1Division of Nephrology, University Health Network, Toronto, Canada.
Clinical Nephrology
|February 24, 2001
Summary
Fibrate medications, used for high cholesterol, can cause temporary kidney function decline in patients with pre-existing renal issues. This reversible effect highlights the need for caution when prescribing fibrates to at-risk individuals.
Area of Science:
- Nephrology
- Pharmacology
- Cardiovascular Medicine
Background:
- Fibric acid derivatives (fibrates) are widely prescribed for hyperlipidemia.
- A potential, under-recognized side effect of fibrates is renal function impairment.
- This study investigates fibrate-induced changes in kidney function.
Purpose of the Study:
- To review cases of renal function deterioration associated with fibrate therapy.
- To identify patient characteristics and potential mechanisms underlying this adverse effect.
Main Methods:
- Retrospective chart review of 10 patients experiencing renal function changes.
- Data collected included serum creatinine, urea, cyclosporine levels, and medical history.
- Analysis focused on identifying confounding factors for altered renal function.
Main Results:
- Ten male patients with pre-existing renal insufficiency showed elevated creatinine and urea levels during fibrate treatment.
- Creatinine levels significantly increased (p < 0.001) but returned to baseline after fibrate discontinuation.
- No changes in cyclosporine levels or creatine kinase were observed.
Conclusions:
- Fibrate therapy can lead to reversible renal function deterioration in susceptible individuals.
- The exact mechanism remains unclear, but renal hemodynamics are a plausible explanation.
- Caution is advised when prescribing fibrates to patients with existing kidney dysfunction.